CTRC

San Antonio, TX, United States
San Antonio, TX, United States

Time filter

Source Type

News Article | May 10, 2017
Site: www.prnewswire.com

Pancreatitis is a disease which occurs when the pancreas becomes inflamed and internal enzymes irritate and damage the pancreas itself. It can be triggered by physical trauma, specific viral infections, some medications or ingestion of a toxin. Although it is considered rare among children, recent studies have shown that the number of pediatric pancreatitis cases has increased. Children are now susceptible to the disease almost as often as adults, which is approximately 1 in 10,000. "It's widely known that alcohol and smoking are easily identifiable risk factors in adults who develop pancreatitis," said Giefer. "However, determining the underlying causes of the disease in children has been challenging to uncover. This study allowed us to test and evaluate the association between age of onset and characteristics of patients with ARP and CP." The most significant findings of the study emerged from the youngest cohort. In patients ages five and below with early-onset pancreatitis, 71 percent possessed at least one pancreatitis-associated gene mutation. This number was significantly greater than the group with later-onset pancreatitis. The two common genetic mutations found in the group with early-onset pancreatitis were cationic trypsinogen (PRSS1) and chymotrypsin C (CTRC). PRSS1 mutations were found in 43 percent of patients, while CTRC was found in 14 percent. "Building upon previous data related to the PRSS1 mutations found in patients with early-onset pancreatitis, we learned that combined with our current data, patients with PRSS1 are more likely to have an aggressive disease course," said Giefer. "The more we understand and discover important details such as this, the closer we are to developing treatments that could modify the disease course in patients." Further research will investigate whether the disease course, response to treatment and outcomes are dependent on the age of the first pancreatitis attack in children. "Overall, this research sheds light on a disease that not only affects adults, but an increasing number of children," said Giefer. "The findings provide us with an improved understanding of the genetic factors involved in early-onset pancreatitis, which will help the pediatric community to improve the evaluation and treatment process for patients." To read the article, please visit The Journal of Pediatrics website. About Seattle Children's Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients. Ranked as one of the top five children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-links-genetics-to-early-onset-pancreatitis-in-pediatric-patients-300455388.html


News Article | May 10, 2017
Site: www.eurekalert.org

Findings show certain genetic mutations and family history are common risk factors in children diagnosed with acute recurrent and chronic pancreatitis before age 6 A study published today in The Journal of Pediatrics suggests that early-onset pancreatitis in children is strongly associated with certain genetic mutations and family history of pancreatitis. Dr. Matthew Giefer, director of gastrointestinal endoscopy at Seattle Children's Hospital, and colleagues analyzed 342 children ages 0-18 with acute recurrent pancreatitis (ARP) and chronic pancreatitis (CP) from INSPPIRE (International Study Group of Pediatric Pancreatitis: In search for a cure), the nation's first and only multicenter, National Institutes of Health-funded pediatric pancreatitis registry, led by Dr. Aliye Uc of University of Iowa Stead Family Children's Hospital. Three age cohorts were examined; children ages 5 and below, 6 to 11 and 12 to 18. The youngest cohort of children, ages 5 and below, was defined as having early-onset pancreatitis. Pancreatitis is a disease which occurs when the pancreas becomes inflamed and internal enzymes irritate and damage the pancreas itself. It can be triggered by physical trauma, specific viral infections, some medications or ingestion of a toxin. Although it is considered rare among children, recent studies have shown that the number of pediatric pancreatitis cases has increased. Children are now susceptible to the disease almost as often as adults, which is approximately 1 in 10,000. "It's widely known that alcohol and smoking are easily identifiable risk factors in adults who develop pancreatitis," said Giefer. "However, determining the underlying causes of the disease in children has been challenging to uncover. This study allowed us to test and evaluate the association between age of onset and characteristics of patients with ARP and CP." The most significant findings of the study emerged from the youngest cohort. In patients ages five and below with early-onset pancreatitis, 71 percent possessed at least one pancreatitis-associated gene mutation. This number was significantly greater than the group with later-onset pancreatitis. The two common genetic mutations found in the group with early-onset pancreatitis were cationic trypsinogen (PRSS1) and chymotrypsin C (CTRC). PRSS1 mutations were found in 43 percent of patients, while CTRC was found in 14 percent. "Building upon previous data related to the PRSS1 mutations found in patients with early-onset pancreatitis, we learned that combined with our current data, patients with PRSS1 are more likely to have an aggressive disease course," said Giefer. "The more we understand and discover important details such as this, the closer we are to developing treatments that could modify the disease course in patients." Further research will investigate whether the disease course, response to treatment and outcomes are dependent on the age of the first pancreatitis attack in children. "Overall, this research sheds light on a disease that not only affects adults, but an increasing number of children," said Giefer. "The findings provide us with an improved understanding of the genetic factors involved in early-onset pancreatitis, which will help the pediatric community to improve the evaluation and treatment process for patients." To read the article, please visit The Journal of Pediatrics website. Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients. Ranked as one of the top five children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho - the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.


News Article | May 16, 2017
Site: www.prnewswire.com

"We are pleased to welcome CTN into the OCHIN family of companies. CTN, with their robust infrastructure and expert staff, perfectly complements the work OCHIN is doing in California. Our combined capabilities and resources strengthen our ability to achieve our mission and ultimately help the safety-net population achieve health equity, and amplifies our collective voice across the nation," said Abby Sears, CEO and President of OCHIN. "We are thrilled about our new partnership with OCHIN. The coming together of our organizations enables the pooling of the resources necessary to more expansively deliver services to improve access and care throughout California. The strength of our combined customer base and infrastructure provides us the capacity to build out a statewide physical presence that will benefit communities across California," said Eric Brown, President of CTN. CTN will continue to operate as a California-based 501(c)(3) nonprofit headquartered in California. Portland, Oregon, nonprofit OCHIN is one of the largest and most successful health information and innovation networks, serving over 450 organizations comprised of more than 10,000 clinicians across the nation with solutions that improve the integration and delivery of health care services. As a learning organization, OCHIN started with a commitment to deliver health information technology support and services and has continued to provide its expanding community of customers and partners with the innovative tools, knowledge, and voice needed to participate in the national health care landscape. For more information, visit www.ochin.org. CTN is California's leading agency focusing on increasing access to quality health care with a focus on California's rural and medically underserved communities. As a 501(c)(3) nonprofit company, CTN is the product of an unprecedented coalition of stakeholders, including health care providers, health plans, technology providers, government agencies, and others that are working together to create a telecommunications and health information technology infrastructure that allows California's rural and medically underserved urban communities access to a broad range of services to expand and improve the quality of health care delivery. CTN also operates the California Telehealth Resource Center (CTRC), which is the Health Resources and Services Administration (HRSA) funded organization focused on expanding telehealth awareness, training, and adoption in California. For more information, please visit www.caltelehealth.org or connect with CalTeleHealth on Facebook, Twitter and YouTube. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/california-telehealth-network-ctn-joins-the-ochin-family-of-companies-300458831.html


News Article | May 16, 2017
Site: www.eurekalert.org

PITTSBURGH, May 16, 2017 - One in five patients who undergo one of the most popular weight-loss surgical procedures is likely to develop problems with alcohol, with symptoms sometimes not appearing until years after their surgery, according to one of the largest, longest-running studies of adults who got weight-loss surgery. The finding--reported online today in Surgery for Obesity and Related Diseases, the journal of the American Society for Metabolic and Bariatric Surgery--indicates that bariatric surgery patients should receive long-term clinical follow-up to monitor for and treat alcohol use disorder, which includes alcohol abuse and dependence. "We knew there was an increase in the number of people experiencing problems with alcohol within the first two years of surgery, but we didn't expect the number of affected patients to continue to grow throughout seven years of follow-up," said lead author Wendy C. King, Ph.D., associate professor of epidemiology at the University of Pittsburgh Graduate School of Public Health. She and her team discovered that 20.8 percent of participants developed symptoms of alcohol use disorder within five years of Roux-en-Y gastric bypass (RYGB). In contrast, only 11.3 percent of patients who underwent gastric banding reported problem alcohol use. Starting in 2006, King and her colleagues followed more than 2,000 patients participating in the National Institutes of Health-funded Longitudinal Assessment of Bariatric Surgery-2 (LABS-2), a prospective observational study of patients undergoing weight-loss surgery at one of 10 hospitals across the United States. RYGB, a surgical procedure that significantly reduces the size of the stomach and changes connections with the small intestine, was the most popular procedure, with 1,481 participants receiving it. The majority of the remaining participants, 522 people, had a less invasive procedure--laparoscopic adjustable gastric banding--where the surgeon inserts an adjustable band around the patient's stomach, lessening the amount of food the stomach can hold. That procedure has become less popular in recent years because it doesn't result in as much weight loss as RYGB. Both groups of patients increased their alcohol consumption over the seven years of the study; however, there was only an increase in the prevalence of alcohol use disorder symptoms, as measured by the Alcohol Use Disorders Identification Test, following RYGB. Among patients without alcohol problems in the year prior to surgery, RYGB patients had more than double the risk of developing alcohol problems over seven years compared to those who had gastric banding. "Because alcohol problems may not appear for several years, it is important that doctors routinely ask patients with a history of bariatric surgery about their alcohol consumption and whether they are experiencing symptoms of alcohol use disorder, and are prepared to refer them to treatment," said King. The American Society for Metabolic and Bariatric Surgery currently recommends that patients be screened for alcohol use disorder before surgery and be made aware of the risk of developing the disorder after surgery. Additionally, the society recommends that high-risk groups be advised to eliminate alcohol consumption following RYGB. However, given the data, King suggests that those who undergo RYGB are a high-risk group, due to the surgery alone. The LABS-2 study was not designed to determine the reason for the difference in risk of alcohol use disorder between surgical procedures, but previous studies indicate that, compared with banding, RYGB is associated with higher and quicker elevation of alcohol in the blood. Additionally, some animal studies suggest that RYGB may increases alcohol reward sensitivity via changes in genetic expression and the hormone system affecting the areas of the brain associated with reward. In addition to RYGB, the LABS-2 study identified several personal characteristics that put patients at increased risk for developing problems with alcohol, including being male and younger, and having less of a social support system. Getting divorced, a worsening in mental health post-surgery and increasing alcohol consumption to at least twice a week also were associated with a higher risk of alcohol use disorder symptoms. King and her team found that although RYGB patients were nearly four times as likely to report having received substance use disorder treatment compared with banding patients, relatively few study participants reported such treatment. Overall, 3.5 percent of RYGB patients reported getting substance use disorder treatment, far less than the 21 percent of patients reporting alcohol problems. "This indicates that treatment programs are underutilized by bariatric surgery patients with alcohol problems," said King. "That's particularly troubling given the availability of effective treatments." Additional authors on this study are Jia-Yuh Chen, Ph.D., and Gretchen E. White, M.P.H., both of Pitt Public Health; Anita P. Courcoulas, M.D., M.P.H., of UPMC; Gregory F. Dakin, M.D., and Alfons Pomp, M.D., both of Weill Cornell Medical College; Scott G. Engel, Ph.D., and James E. Mitchell, M.D., both of the Neuropsychiatric Research Institute in Fargo, N.D.; David R. Flum, M.D., and Marcelo W. Hinojosa, M.D., both of the University of Washington; Melissa A. Kalarchian, Ph.D., of Pitt and Duquesne University; Samer G. Mattar, M.D., and Bruce M. Wolfe, M.D., both of the Oregon Health Sciences University; Walter J. Pories, M.D., of East Carolina University; Kristine J. Steffen, Pharm.D., Ph.D., of the Neuropsychiatric Research Institute and North Dakota State University; and Susan Z. Yanovski, M.D., of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This clinical study was a cooperative agreement funded by the NIDDK. Grant numbers: Data Coordinating Center - U01 DK066557; Columbia - U01-DK66667 (in collaboration with Cornell University Medical Center CTSC, grant UL1-RR024996); University of Washington - U01-DK66568 (in collaboration with CTRC, grant M01RR-00037); Neuropsychiatric Research Institute - U01-DK66471; East Carolina University - U01-DK66526; UPMC - U01-DK66585 (in collaboration with CTRC, grant UL1-RR024153); and Oregon Health & Science University - U01-DK66555. The University of Pittsburgh Graduate School of Public Health, founded in 1948 and now one of the top-ranked schools of public health in the United States, conducts research on public health and medical care that improves the lives of millions of people around the world. Pitt Public Health is a leader in devising new methods to prevent and treat cardiovascular diseases, HIV/AIDS, cancer and other important public health problems. For more information about Pitt Public Health, visit the school's Web site at http://www. .


SAN ANTONIO -- A sentinel lymph node biopsy (SLNB) during surgery that showed no signs of cancer was associated with a low risk for breast cancer recurrence in the axillary (armpit) lymph nodes for patients with large, operable breast tumors and no clinical signs of the cancer in the axillary lymph nodes prior to neoadjuvant (presurgery) chemotherapy, according to data from the GANEA 2 clinical trial presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6-10. "Axillary lymph node dissection (ALND), which is an invasive surgical procedure in which many of the lymph nodes in the armpit are removed, is often performed to check whether a patient's cancer has spread outside the breast after neoadjuvant chemotherapy," said Jean-Marc Classe, MD, PhD, head of surgery at the Institut de Cancerologie de l'Ouest René Gauducheau in Nantes, France. "ALND has a high risk for serious complications and long-term sequelae. So we wanted to assess the feasibility and safety of the less invasive procedure of SLNB for patients treated with neoadjuvant chemotherapy for a large breast cancer. "We found that for patients with no proof of cancer in the axillary lymph nodes before neoadjuvant chemotherapy, SLNB during the surgery after neoadjuvant chemotherapy was safe because those who had a negative SNLB and did not have an ALND had a very low risk of an axillary relapse at three years after surgery," continued Classe, who is also professor of oncology at the Medical University in Nantes. "We had expected more axillary lymph node relapses than we observed, so this is very exciting and will hopefully mean that more patients are spared the potential complications of invasive ALND." Classe and colleagues enrolled in the trial 590 patients with large, operable breast tumors who had no cancer in the lymph nodes as determined by axillary sonography with fine needle cytology. All patients received neoadjuvant chemotherapy and then underwent surgery and SLNB. Cancer cells were detected in the SLNB samples from 139 patients. These patients all then underwent ALND. No cancer cells were detected in the SLNB samples from 432 patients. Among these 432 patients, follow-up was available for 416. Median follow-up for these patients was 35.8 months. At three years, disease-free survival in the patients who had no cancer in the SLNB sample and, therefore, did not receive ALND was 94.8 percent. One patient had homolateral axillary lymph node relapse. The other nine relapses were metastatic (n=3) or recurrences in the breasts (n=6). Overall survival was 98.7 percent. "The disease-free and overall survival results we observed for the patients who underwent only an SLNB after neoadjuvant chemotherapy are comparable with the historical survival rates for patients in this situation who have ALND rather than SLNB," said Classe. "Therefore, an ALND could be avoided by patients who have no signs of cancer in the axillary lymph nodes following a sonographic axillary assessment prior to neoadjuvant chemotherapy and SLNB during surgery after neoadjuvant chemotherapy." Classe noted that longer follow-up of the patients is needed to further confirm the safety of SLNB for these patients. This study was funded by a grant from the Institut National du Cancer. Classe declares no conflicts of interest. Title: Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): follow-up of a prospective multi-institutional cohortPresentation: Wednesday, Dec. 7, General Session 2 - Hall 3, 4:45 p.m. CT To interview Jean-Marc Classe, contact Julia Gunther at julia.gunther@aacr.org or 267-250-5441. The mission of the 2016 San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR's scientific prestige in basic, translational, and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. For more information about the symposium, please visit http://www. .


REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce...


News Article | December 9, 2016
Site: www.eurekalert.org

SAN ANTONIO -- Breast cancer mortality rates continue to decline in many nations, but a review of mortality trends in 47 countries around the world indicates some significant disparities, particularly in South Korea and some Latin American nations, according to results presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6-10. "Breast cancer is by far the primary cancer site in women and, worldwide, represents a quarter of all cancers in women," said the study's lead author, Cécile Pizot, MSc, at the International Prevention Research Institute in Lyon, France. "Comparing mortality trends between countries helps identify which health care systems have been the most efficient at reducing breast cancer mortality." In this study, Pizot and colleagues extracted information on breast cancer deaths from the World Health Organization database and calculated mortality rates over the years 1987-2013, stratifying results according to age groups. Overall, breast cancer mortality declined in 39 out of 47 countries, including the United States and most developed European nations. England and Wales had the sharpest drop in mortality, with a 46 percent decline. Pizot said this trend was to be expected, due to advances in detection and treatment over the past few decades. Latin American nations experienced scattered increases in mortality; for example, Brazil and Colombia saw mortality rates increase in women of all age groups, while in Argentina and Chile mortality rates decreased in all women. South Korea had the most dramatic increase in breast cancer mortality, with an 83 percent increase overall and higher mortality in every age group. However, the breast cancer mortality rate is still lower than the rate in the United States (5.3 per 100,000 women in South Korea compared with 14 per 100,000 women in the United States in the 2011-2013 period). "South Korea has experienced major societal changes since the 1950s and quickly evolved from an agricultural, developing country to a highly industrialized and Westernized country," Pizot said. "Such quick changes might explain the considerable shift in cancer mortality." Other highlights of the study: "This finding underlines the difficulty of isolating a single, common factor that would have a major influence on mortality trends," Pizot said, adding that future research on breast cancer mortality should focus on other facets of breast cancer management, including risk factors, drug therapies, access to care, and the use of multidisciplinary teams. "Differences in health care systems and patient management could explain discrepancies in mortality reduction between similar countries," Pizot said. "However, there is at present little data comparing the management of breast cancer patients across countries." Pizot said a limitation of the study is that data were unavailable for many Latin American, Asian, and African nations. This study was funded internally by the International Prevention Research Institute. Pizot has no conflicts of interest. Abstract Publication Number: P5-08-04 Title: Overview of breast cancer mortality trends in the world Presentation: Friday, Dec. 9, Poster Session 5, 5 p.m. CT The mission of the 2016 San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR's scientific prestige in basic, translational, and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. For more information about the symposium, please visit http://www. . To interview Cécile Pizot, contact Julia Gunther at julia.gunther@aacr.org or 267-250-5441.


SEATTLE, Dec. 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced advances in precision oncology using the Prosigna® Breast Cancer Gene Signature Assay and the PAM50 gene signature, the basis for Prosigna, will be presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). In addition, numerous customers will be presenting data generated using NanoString’s nCounter® Analysis System, including several involving immuno-oncology. "The volume and impact of the clinical research being presented at the SABCS underscores our commitment to improving the lives of breast cancer patients," said Brad Gray, president and chief executive officer of NanoString Technologies. “These studies demonstrate that our Prosigna Assay can improve decision-making in early-stage breast cancer today, and that a modified companion diagnostic version of this assay has future potential in triple negative breast cancer. The studies also show that our nCounter Analysis System is continuing to grow in prominence as an important tool among breast cancer researchers.” NanoString and its collaborators will present three oral presentations and fourteen posters covering Prosigna/PAM50 and other nCounter-based research at SABCS, which is being held December 6-10, 2016. Following are details for each presentation of data involving Prosigna and the PAM50 gene signature (all times are in Central Standard Time): Additional abstracts and posters demonstrate the diverse applications and robust performance of the nCounter® Analysis System in immuno-oncology and biomarker validation, including: You can learn more about the Prosigna Breast Cancer Gene Signature at booth #525. About the Prosigna® Breast Cancer Prognostic Gene Signature Assay and nCounter® Dx Analysis System The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence of disease. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma. The Prosigna Assay requires minimal hands-on time and runs on NanoString's proprietary nCounter® Dx Analysis System, which offers a reproducible and cost-effective way to profile many genes simultaneously with high sensitivity and precision. The nCounter Dx Analysis System is a highly automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays. The system is available in the multi-mode FLEX configuration, which is designed to meet the needs of high-complexity clinical laboratories seeking a single platform with the flexibility to run the Prosigna Breast Cancer Assay and, when operated in the "Life Sciences" mode, process translational research experiments and multiplexed assays developed by the laboratory. In the United States, the Prosigna Assay is 510(k) cleared for use on the nCounter Dx Analysis System, and is available for diagnostic use when ordered by a physician. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as Canada, Israel, Australia, New Zealand, Argentina, Thailand, South Africa, Turkey and Hong Kong. In the U.S., the Prosigna Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as: (1) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors or (2) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1-3 nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with four or more positive nodes. Other uses of Prosigna or the PAM50 panel in studies as described in this press release are for Investigational Use Only, or Research Use Only. For more information, please visit www.prosigna.com. About NanoString Technologies, Inc. NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,350 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com. The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.


News Article | November 14, 2016
Site: www.marketwired.com

Conference Call to be Held Monday, November 14, 2016 at 5:30pm Eastern Time SEATTLE, WA--(Marketwired - Nov 14, 2016) - Atossa Genetics Inc. ( : ATOS) today announced Third Quarter ended September 30, 2016 financial results and provided an update on recent company developments. Dr. Steve Quay, President and CEO, commented, "We are pleased with our continuing achievements in the Third Quarter 2016, which enabled us to strengthen Atossa's foundation and further our drug development program goals. Our settlement with Besins Healthcare, and our recently completed capital raise provided Atossa with approximately $4 million in additional capital with which to advance our two exciting drug development programs." Dr. Quay added, "We continue to make progress on both of our drug development programs: Our Phase 2 clinical trial of intraductal fulvestrant is proceeding and I am pleased to report that the study has been accepted for presentation at the CTRC-AARC San Antonio Breast Cancer Symposium to be held December 6-10, 2016. We also made strong progress with our proprietary oral endoxifen, which we are developing for breast cancer patients who do not respond to tamoxifen. The initial drug supply for Phase 1 and Phase 2 studies is under development and we'll provide updates as we head towards the clinical studies." Total operating expenses were approximately $1.6 million and $5.4 million for the three months and nine months ended September 30, 2016, respectively, consisting of general and administrative (G&A) expenses of approximately $1.5 million and $5.0 million, respectively and R&D expenses of approximately $85,000 and $404,000 respectively. As a result of the sale of NRLBH, operating expenses related to the NRLBH are presented separately as discontinued operations for the three months and nine months ended September 30, 2015. Operating expenses from continuing operations for the three months and nine months ended September 30, 2016 decreased approximately $2.2 million and $4.9 million, or 57.9% and 47.6% respectively, from approximately $3.8 million and $10.3 million for the three months and nine months ended September 30, 2015, respectively, which consisted of G&A expenses of approximately $2.4 million and $7.2 million, respectively, R&D expenses of approximately $949,000 and $1.9 million, respectively, and selling expenses of approximately $499,000 and $1.2 million, respectively. The decrease in operating expenses is mainly attributed to the 2015 launch of new devices and services which are not being pursued in 2016 and investing more in new R&D programs in the first quarter of 2015 compared to 2016. Net loss for the nine months ended September 30, 2016 was $3.8 million and cash and cash equivalents were approximately $4.4 million. Management will host a business update conference call on Monday November 14, 2016 at 5:30 pm eastern time to review Third Quarter ended September 30, 2016 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session. To listen to the call by phone, interested parties within the U.S. should call 1-844-824-3830 and International callers should call 1-412-317-5140. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar. A replay of the call will be available approximately one hour after the end of the call through December 14, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10096671. Atossa Genetics Inc, is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com. Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


News Article | December 23, 2016
Site: www.marketwired.com

TORONTO, ON--(Marketwired - Dec 22, 2016) - A WireIE, uma operadora de rede por atacado especializada em implantação de redes Ethernet de Transportadoras certificadas MEF nos mercados sem atendimento do Canadá, comemora um ano com muito crescimento e sucesso. A empresa canadense WireIE presente de costa a costa e com a meta de aumentar ainda mais o escopo das suas redes de alta disponibilidade, seguras e confiáveis nos mercados sem atendimento no Canadá permitiu que a WireIE aumentasse 20%, em parceria com suas transportadores de atacado em 2016. Especificamente, o crescimento acelerado do governo federal, indústria de petróleo e de gás, ehealth, bancos e outras. "O nível de crescimento que tivemos em 2016 é quase imbatível na indústria", disse Rob Barlow, CEO da WireIE, "Eu falei com muitos executivos do setor e todos ficaram surpresos com o nosso crescimento". A WireIE também cresceu no exterior, sendo que 25% do crescimento da empresa sendo realizado nas Américas, e novos projetos na Argentina e no Caribe, aumentando a presença e os elogios globais. A indústria também reconheceu o crescimento da WireIE, com dois prêmios para a equipe da WireIE. O primeiro prêmio foi em maio na Global Telecom Business Innovation Awards. "Ficamos contentíssimos em receber este prêmio. Ele reconheceu as soluções inovadoras da WireIE nos mercados não atendidos e localizados em diferentes áreas", disse o CEO, Rob Barlow. A Europa foi muito boa para a WireIE este ano, após outro prêmio que recebemos em novembro. "Em Paris, recebemos o prêmio de Melhor Projeto da América do Norte", disse Barlow, acrescentando: "Foi um grande privilégio receber esses dois prêmios". Os eventos europeus são bem conhecidos da indústria, sendo que a conferência Capacity Europe é uma das mais estabelecidas e bem consideradas da indústria de telecomunicações, com mais de 2.000 executivos de 80 países. Os dois prêmios confirmam a meta da WireIE de criar um mundo mais conectado e de viabilizar parcerias futuras para que as redes sejam a prova do futuro. Com uma presença global cada vez maior, no mês passado Barlow foi convidado para fazer uma palestra em duas Mesas Redondas de CEOs em LA. "IOT & The Data Center: Talking Cloud, Power and Performance" e "IOT & Cybersecurity: Risks in the Supply Chain, Privacy and Defense." As Mesas Redondas foram uma oportunidade para os líderes do setor compartilharem suas previsões para o futuro da tecnologia e das telecomunicações e para participarem de sessões de Perguntas e Respostas moderadas por analistas e jornalistas do setor. Devido ao recente anúncio da CTRC, a WireIE está muito contente com o fato de o governo do Canadá ter reconhecido a conexão com a Internet como um serviço básico. A WireIE ultrapassou um limite novo do total de circuitos ligados e conectados nos mercados sem atendimento em 2016, com sua rápida expansão, em suporte à exigência do governo para 2017. WireIE A WireIE é a operadora de telecomunicações canadense especializada na implantação de redes Ethernet 2.0 Certificadas MEF para os mercados não atendidos. A performance comprovada da WireIE, apoiada pelos SLAs líderes do setor, estabeleceu a transportadora como a principal provedora para exigências de rede de missão crítica, em todos os verticais da indústria, inclusive Petróleo e Gás, Mineração, Utilidades Públicas, Saúde, Finanças, Varejo e Setor Público. Libere o potencial com a WireIE - visite www.wireie.com e siga-nos no Twitter @WireIE.

Loading CTRC collaborators
Loading CTRC collaborators